Contrary to the outcome observed for Patient 3, neratinib efficacy has been reported in a ERBB2 I655V transmembrane domain mutation in different lung cancer cell lines52, suggesting the S653C mutation may be functionally different than the I655V mutation. This evidence concerns the gene ERBB2 and lung cancer.